The price of ANIK is predicted to go up -0.85%, based on the high correlation periods with MNDO. The similarity of these two price pattern on the periods is 97.91%.
ANIK
MNDO
Down: -0.85%Similarity: 97.91%
ANIK Revenue Forecast
ANIK EPS Forecast
ANIK FAQs
What is ANIK revenue forecast for next quarter?
The market consensus for ANIK's revenue in the upcoming quarter is projected to be approximately $28.125M USD.
What is ANIK eps forecast for next quarter?
The market consensus for ANIK's eps in the upcoming quarter is projected to be approximately $0.1 USD.
Barrington analyst Michael Petusky lowered the firm's price target on Anika Therapeutics to $25 from $37 and keeps an Outperform rating on the shares after Q3 results fell short of expectations and the company "materially reduced" its previous adjusted EBITDA guidance for FY24. Weakening OA pain volumes and softer pricing in the U.S. were the primary factors in "the more pessimistic outlook," notes the analyst, who notes the firm's target is based on its FY25 adjusted EBITDA estimate plus $50M of value it adds for the company's "two potential needle-mover products," namely Cingal and Hyalofast, that have completed pivotal trials but have not yet received U.S. approval.